In preclinical models, inhibition of PGE2 production through COX2 inhibitors, specifically acetylsalicylic acid and celecoxib, led to both the suppression of gliomagenesis and reduction of MDSCs in the tumor microenvironment through a decrease in CCL2 (Fujita et al., 2011; Shono et al., 2020). The gene discussed is CCL2; the disease is neoplasm.